Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Change in Accured Expenses (2016 - 2025)

Palisade Bio (PALI) has disclosed Change in Accured Expenses for 16 consecutive years, with $429000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses rose 166.46% to $429000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $172000.0, a 119.91% increase, with the full-year FY2024 number at -$56000.0, up 88.62% from a year prior.
  • Change in Accured Expenses was $429000.0 for Q3 2025 at Palisade Bio, up from $74000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $817000.0 in Q4 2022 to a low of -$1.1 million in Q2 2024.
  • A 5-year average of -$4187.5 and a median of $117500.0 in 2024 define the central range for Change in Accured Expenses.
  • Biggest YoY gain for Change in Accured Expenses was 308.47% in 2024; the steepest drop was 1434.72% in 2024.
  • Palisade Bio's Change in Accured Expenses stood at $183000.0 in 2021, then soared by 346.45% to $817000.0 in 2022, then tumbled by 165.48% to -$535000.0 in 2023, then skyrocketed by 151.03% to $273000.0 in 2024, then skyrocketed by 57.14% to $429000.0 in 2025.
  • Per Business Quant, the three most recent readings for PALI's Change in Accured Expenses are $429000.0 (Q3 2025), $74000.0 (Q2 2025), and -$604000.0 (Q1 2025).